Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
High Grade Primary Breast Lymphoma: is it a Different Clinical Entity?
Authors
Christophe Fruchart
Yves Denoux
Jacques Chasle
Anne Marie Peny
Véronique Boute
Jean Michel Ollivier
Jean Yves Genot
Jean-Jacques Michels
Publication date
01-10-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-5088-8

Other articles of this Issue 3/2005

Breast Cancer Research and Treatment 3/2005 Go to the issue

Clinical Trial

Short Versus Long-term Postoperative Drainage of the Axilla After Axillary Lymph Node Dissection. A Prospective Randomized Study

Epidemiology

Estrogen Metabolizing Polymorphisms and Breast Cancer Risk Among Older White Women

Invited Commentary

Adenoid Cystic Carcinoma of Breast, a Special Histopathologic Type with Excellent Prognosis

Report

Measurement of Glut-1 Expression Using Tissue Microarrays to Determine a Race Specific Prognostic Marker for Breast Cancer

Report

Cyclic Induction of Senescence with Intermittent AZT Treatment Accelerates both Apoptosis and Telomere Loss

Report

Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal Women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits